- Home
- MUFG vs GILD Comparison
MUFG vs GILD Comparison
Compare MUFG & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUFG
- GILD
- Stock Information
- Founded
- MUFG 1880
- GILD 1987
- Country
- MUFG Japan
- GILD United States
- Employees
- MUFG N/A
- GILD N/A
- Industry
- MUFG Commercial Banks
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MUFG Finance
- GILD Health Care
- Exchange
- MUFG Nasdaq
- GILD Nasdaq
- Market Cap
- MUFG 167.5B
- GILD 140.8B
- IPO Year
- MUFG 2001
- GILD 1992
- Fundamental
- Price
- MUFG $14.56
- GILD $119.41
- Analyst Decision
- MUFG
- GILD Buy
- Analyst Count
- MUFG 0
- GILD 24
- Target Price
- MUFG N/A
- GILD $114.26
- AVG Volume (30 Days)
- MUFG 3.7M
- GILD 6.0M
- Earning Date
- MUFG 08-04-2025
- GILD 08-07-2025
- Dividend Yield
- MUFG 2.41%
- GILD 2.65%
- EPS Growth
- MUFG N/A
- GILD 496.80
- EPS
- MUFG 0.75
- GILD 5.01
- Revenue
- MUFG $37,710,895,911.00
- GILD $28,863,000,000.00
- Revenue This Year
- MUFG $196.53
- GILD $1.91
- Revenue Next Year
- MUFG $9.99
- GILD $3.75
- P/E Ratio
- MUFG $18.83
- GILD $23.83
- Revenue Growth
- MUFG N/A
- GILD 3.81
- 52 Week Low
- MUFG $9.51
- GILD $72.43
- 52 Week High
- MUFG $15.03
- GILD $121.38
- Technical
- Relative Strength Index (RSI)
- MUFG 63.13
- GILD 63.42
- Support Level
- MUFG $13.62
- GILD $108.54
- Resistance Level
- MUFG $14.18
- GILD $114.57
- Average True Range (ATR)
- MUFG 0.20
- GILD 2.68
- MACD
- MUFG 0.03
- GILD 0.16
- Stochastic Oscillator
- MUFG 75.95
- GILD 85.21
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).